SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : QLT PhotoTherapeutics (QLTI)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Bill Tomko who wrote (92)3/7/1997 2:42:00 AM
From: John K_k   of 1321
 
A number of announcements were released today at "THE INTERNATIONAL PHOTODYNAMIC THERAPY SYMPOSIUM" in Tokyo.

1. Photodynamic therapy with Photofrin (Qlt's lead product) was shown to "provide long-term tumor response". "Dr. Kato used PDt with Photofrin to treat superficial early-stage lung cancers between 1989 and 1992 and found complete response in 90.6% of 64 squamous cell carcinomas treated. Five years later 62.5% of the 64 lesions had not recurred.

2. Dr. Kato estimated that in Japan, photodynamic therapy with Photofrin is 40% less costly than surgery.

3. Unlike surgery and radiation, Photofrin does not preclude further treatmeant with other cancer drugs.

4. Dr. Michel Leroy of Centre Medico-Chirurgical foch, Paris, showed that "88% of patients with inoperable early-stage, superficial lung cancer achieved a complete tumor response PDt with photofrin in clinical studies conducted in France between 1990 and 1993."

5. Photofrin is the only product approved anywhere in the world as a cancer treatment using PDT(photodynmaic therapy).

Hope this clears up your misinformed posting for other readers
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News